BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Zhou S, Chen C, Ma L, Luo D, Tian X, Dong X, Zhou Y, Yang Y, Cui Y. Therapeutic potential of pyruvate therapy for patients with mitochondrial diseases: a systematic review. Ther Adv Endocrinol Metab 2020;11:2042018820938240. [PMID: 32695307 DOI: 10.1177/2042018820938240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Laemmle A, Steck AL, Schaller A, Kurth S, Perret Hoigné E, Felser AD, Slavova N, Salvisberg C, Atencio M, Mochel F, Nuoffer JM, Gautschi M. Triheptanoin - Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency. Mol Genet Metab Rep 2021;29:100814. [PMID: 34712577 DOI: 10.1016/j.ymgmr.2021.100814] [Reference Citation Analysis]
2 Zhou FQ. NAD+, Senolytics, or Pyruvate for Healthy Aging? Nutr Metab Insights 2021;14:11786388211053407. [PMID: 34720589 DOI: 10.1177/11786388211053407] [Reference Citation Analysis]
3 Zwolak I, Wnuk E. Effects of Sodium Pyruvate on Vanadyl Sulphate-Induced Reactive Species Generation and Mitochondrial Destabilisation in CHO-K1 Cells. Antioxidants 2022;11:909. [DOI: 10.3390/antiox11050909] [Reference Citation Analysis]